The Innovation and Value Initiative today announced that it is in the process of releasing a new model and value tool to evaluate treatments for for EGFR-positive non-small cell lung cancer (NSCLC). More details on the model (named the IVI-NSCLC model) are available here, which includes a study protocol and model timeline.
Oncology is an area of immense clinical need and a primary driver of healthcare spending, making it a prime target for assessment of the value of available medical interventions. IVI’s next Open-Source Value Project (OSVP) model will focus on non-small cell lung cancer (NSCLC). Specifically, the IVI-NSCLC model will focus on sequential treatment strategies for patients with epidermal growth factor receptor positive (EGFR+) NSCLC.
IVI’s open-source value model for EGFR+ NSCLC treatments will facilitate patient-centered, robust, and relevant evaluation of the value of care for an often devastating disease. Development of this model reflects IVI’s vision of a transparent process for understanding value in the local setting, especially from the patient perspective.
The full model and value tool are due out to the public November 29 according to the IVI-NSCLC timeline.